Comparison of [18F]fluciclovine and [18F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients

• DOI: 10.1007/s11307-022-01734-0
• Publication Date: 2022-05-02T18:02:42Z
• Authors: Caroline Stokke; Jakob Nordberg Nø...; Hilde Feiring Phi...; Alexander Sherwani; Syed Nuruddin; James Connelly; Fredrik Schjesvold; Mona-Elisabeth Re...
• Keywords: PET-CT

Abstract Purpose [ 18 F]FDG PET/CT in multiple myeloma (MM) is currently the best technology to demonstrate patchy and extramedullary disease. However, PET has some limitations, imaging with alternative tracers should be explored. In this study, we aimed evaluate performance of F]fluciclovine compared newly diagnosed MM patients. Procedures Thirteen transplant eligible patients were imaged both within 1 week a prospective study. The subjects visually assessed positive or negative for number lesions SUV max selected measured tracers. Furthermore, tracer uptake ratios obtained by dividing lesion blood bone marrow . Between-group differences correlations paired t -tests Pearson tests. Bone SUVs plasma cell percentage biopsy samples. Results Nine positively (69%) 12 positives (92%). All had scans that qualitatively scored as easier interpret than scans. was also higher; seven nine distinct hot spots on fewer no visible PET. mean values 8.2 3.8 F]FDG, respectively. tumour 6.4 2.0 between 2.1 1.5 F]FDG. significantly higher (all p < 0.01). Local os ilium cells biopsies linearly correlated ( = 0.048). There significant 0.82). Conclusions Based pilot promising MM. visual semi-quantitative evaluations indicate can out-perform at diagnosis.